

Xue Yang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8506524/xue-yang-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

240
citations

8
h-index

14
g-index

32
ext. papers

374
ext. citations

3.9
avg, IF

2.96
L-index

#	Paper	IF	Citations
27	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. <i>Journal of Thoracic Disease</i> , 2021 , 13, 1813-1821	2.6	0
26	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 639892	5.6	5
25	The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index. <i>Frontiers in Oncology</i> , 2021 , 11, 690093	5.3	1
24	First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	6
23	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , 2021 , 9, 33	3.2	7
22	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. <i>Translational Lung Cancer Research</i> , 2021 , 10, 981-994	4.4	4
21	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIa non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2021 , 13, 1799-1812	2.6	0
20	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , 2020 , 20, 590	6.4	
19	Analysis of MET kinase domain rearrangement in NSCLC. <i>Lung Cancer</i> , 2020 , 145, 140-143	5.9	5
18	Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. <i>Thoracic Cancer</i> , 2020 , 11, 1149-1159	3.2	2
17	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. <i>Frontiers in Oncology</i> , 2020 , 10, 626	5.3	5
16	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 892-901	12.9	34
15	Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation. <i>Clinical Lung Cancer</i> , 2020 , 21, e258-e260	4.9	9
14	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. <i>BMC Cancer</i> , 2020 , 20, 666	4.8	8
13	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. <i>Frontiers in Oncology</i> , 2020 , 10, 1137	5.3	3
12	Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. <i>BMC Cancer</i> , 2020 , 20, 793	4.8	6
11	Simultaneous tongue metastasis from malignant pleural mesothelioma: Case report and literature review. <i>Thoracic Cancer</i> , 2020 , 12, 391	3.2	0

10	Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. <i>Thoracic Cancer</i> , 2019 , 10, 1193-1202	3.2	4
9	Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. <i>Thoracic Cancer</i> , 2019 , 10, 1788-1797	3.2	5
8	Optimal first-line treatment for advanced thymic carcinoma. <i>Thoracic Cancer</i> , 2019 , 10, 2081-2087	3.2	6
7	ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. <i>Thoracic Cancer</i> , 2019 , 10, 2088-2095	3.2	14
6	Survival comparison of right and left side non-small cell lung cancer in stage I-IIIa patients: A Surveillance Epidemiology and End Results (SEER) analysis. <i>Thoracic Cancer</i> , 2019 , 10, 459-471	3.2	8
5	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018 , 9, 291-297	3.2	4
4	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , 2018 , 9, 1166-1173	3.2	7
3	Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. <i>BMC Cancer</i> , 2018 , 18, 1171	4.8	17
2	Survival difference between Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017 , 29, 553-560	3.8	10
1	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. <i>Oncotarget</i> , 2016 , 7, 20810-24	3.3	63